Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J6NV
|
|||
| Former ID |
DNCL003205
|
|||
| Drug Name |
GI-5005
|
|||
| Indication | Chronic HCV-1 infection [ICD-11: 1E51.1; ICD-10: B18.2] | Phase 2 | [1] | |
| Hepatitis C virus infection [ICD-11: 1E51.1; ICD-10: B18.2] | Phase 2 | [1] | ||
| Company |
GlobeImmune
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00606086) Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.